A Phase 1b, Multicenter Trial to Evaluate Molecular Determinants of Response to Erlotinib and MK0646 in Advanced Non-Small-Cell Lung Cancer

Trial Profile

A Phase 1b, Multicenter Trial to Evaluate Molecular Determinants of Response to Erlotinib and MK0646 in Advanced Non-Small-Cell Lung Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Dalotuzumab (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Nov 2010 New source identified and integrated (United Kingdom Clinical Research Network).
    • 21 Jun 2010 Planned end date changed from 1 Jun 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top